This is a plain-English translation of the academic paper above, prepared for patients, referring clinicians, and other non-specialist readers. It preserves the structure of the original paper while removing technical jargon. For the full clinical paper, follow the PubMed or DOI links.
Background
The three-year outcomes of patients with knee osteoarthritis receiving an injection of micro-fragmented adipose tissue (MFAT) — the patient’s own fat, gently processed and reinjected into the joint — rather than further surgery.
Rationale
For patients with knee osteoarthritis whose symptoms aren’t severe enough for joint replacement but who have failed standard treatments, options are limited. MFAT is a regenerative-medicine option whose long-term effectiveness has been under-studied.
Results
Across 335 patients, all standard outcome scores (pain, function, quality of life, knee-specific scores) improved significantly at 3 months and the improvement was sustained at 3 years. Most strikingly, the response at 3 months reliably predicted the response at 3 years — meaning patients who do well early can expect that benefit to last.
Implications
For knee osteoarthritis short of needing replacement, MFAT injection is a real option with three-year evidence behind it. The early response is a reliable indicator of whether long-term benefit will follow.
Source: Stanciu N, Heidari N, Slevin M, et al. Predicting Long-Term Benefits of Micro-Fragmented Adipose Tissue Therapy in Knee Osteoarthritis: Three-Year Follow-Up on Pain Relief and Mobility. Journal of Clinical Medicine 2025. PMID: 40648923.
Read original on PubMed → ← Back to research library